Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Family Keeps on Growing: Four Novel Fungal OYEs Characterized.
Robescu MS, Loprete G, Gasparotto M, Vascon F, Filippini F, Cendron L, Bergantino E. Robescu MS, et al. Among authors: vascon f. Int J Mol Sci. 2022 Mar 11;23(6):3050. doi: 10.3390/ijms23063050. Int J Mol Sci. 2022. PMID: 35328465 Free PMC article.
Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates.
Legru A, Verdirosa F, Vo-Hoang Y, Tassone G, Vascon F, Thomas CA, Sannio F, Corsica G, Benvenuti M, Feller G, Coulon R, Marcoccia F, Devente SR, Bouajila E, Piveteau C, Leroux F, Deprez-Poulain R, Deprez B, Licznar-Fajardo P, Crowder MW, Cendron L, Pozzi C, Mangani S, Docquier JD, Hernandez JF, Gavara L. Legru A, et al. Among authors: vascon f. J Med Chem. 2022 Dec 22;65(24):16392-16419. doi: 10.1021/acs.jmedchem.2c01257. Epub 2022 Nov 30. J Med Chem. 2022. PMID: 36450011 Free article.
Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-β-Lactamases and Synergistic Activity on Resistant Bacteria.
Bersani M, Failla M, Vascon F, Gianquinto E, Bertarini L, Baroni M, Cruciani G, Verdirosa F, Sannio F, Docquier JD, Cendron L, Spyrakis F, Lazzarato L, Tondi D. Bersani M, et al. Among authors: vascon f. Pharmaceuticals (Basel). 2023 Dec 2;16(12):1682. doi: 10.3390/ph16121682. Pharmaceuticals (Basel). 2023. PMID: 38139809 Free PMC article.
Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.
Caccese M, Imbevaro S, Feltrin A, Costardi D, Giordano N, Maran M, Martino R, Ottolitri K, Shams M, Vascon F, Roma A, Galiano A, Maruzzo M, Marino D, Lombardi G, Lonardi S, Brunello A, Zagonel V. Caccese M, et al. Among authors: vascon f. Patient Prefer Adherence. 2022 Feb 9;16:353-362. doi: 10.2147/PPA.S351771. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 35173420 Free PMC article.
Bevacizumab in advanced cancer, too much or too little?
Jirillo A, Vascon F, Giacobbo M. Jirillo A, et al. Among authors: vascon f. Ann Oncol. 2008 Oct;19(10):1817-8. doi: 10.1093/annonc/mdn564. Ann Oncol. 2008. PMID: 18809585 Free article. No abstract available.